Abouch Krymchantowski

Dr. Abouch Krymchantowski


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2010 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
AKAbouch Krymchantowski
Abouch Krymchantowski

19 October 2011 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
AKAbouch Krymchantowski
Abouch Krymchantowski
CJCarla da Cunha Jevoux
Carla da Cunha Jevoux
MBMarcelo E. Bigal
Marcelo E. Bigal
A sizeable proportion of migraineurs in need of preventive therapy do not significantly benefit from monotherapy. The objective of the study is to conduct a randomized controlled trial testing whether combination therapy of topiramate and nortriptyline is useful in patients who had less than 50% decrease in headache frequency with the use of the single agents. Patients with episodic migraine were enrolled if they had less than 50% reduction in headache frequency after 8 weeks of using topiramate (TPM) (100 mg/day) or nortriptyline (NTP) (30 mg/day). They were randomized (blinded fashion) to have placebo added to their regimen, or to receive the second medication (combination therapy). Primary endpoint was decrease in number of headache days at 6 weeks, relative to baseline, comparing both groups. Secondary endpoint was proportion of patients with at least 50% reduction in headache frequency at 6 weeks relative to baseline. A total of 38 patients were randomized to receive combination therapy, while 30 continued on monotherapy (with placebo) (six drop outs in the combination group and three for each single drug group). For the primary endpoint, mean and standard deviation (SD) of reduction in headache frequency were 4.6 (1.9) for those in polytherapy, relative to 3.5 (2.3) for those in monotherapy. Differences were significant (p < 0.05]. Similarly, 78.3% of patients randomized to receive polytherapy had at least 50% headache reduction, as compared to 37% in monotherapy (p < 0.04). Finally we conclude that combination therapy (of TPM and NTP) is effective in patients with incomplete benefit using these agents in monotherapy.

6 May 2014 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
PDF file
AKAbouch Krymchantowski
Abouch Krymchantowski
CJCarla da Cunha Jevoux
Carla da Cunha Jevoux

28 May 2020 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
AKAbouch Krymchantowski
Abouch Krymchantowski
CJCarla C. Jevoux
Carla C. Jevoux
AKAna G. Krymchantowski
Ana G. Krymchantowski
RVRodrigo Salvador Vivas
Rodrigo Salvador Vivas
RSRaimundo Silva-Néto
Raimundo Silva-Néto
Medication-overuse headache (MOH) is a common debilitating neurological disorder, with a prevalence of 1% to 7% in general population. It affects more than 60 million people worldwide and provokes ...

10 November 2016 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
PDF file
AKAbouch Krymchantowski
Abouch Krymchantowski
STStewart J. Tepper
Stewart J. Tepper
CJCarla Jevoux
Carla Jevoux
MVMarcelo Valença
Marcelo Valença

15 November 2011 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
PDF file
AKAbouch Krymchantowski
Abouch Krymchantowski
CJCarla da Cunha Jevoux
Carla da Cunha Jevoux